Walleye Capital
SUPN icon

Walleye Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Walleye Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$580K Sell
11,214
-17,483
-61% -$890K ﹤0.01% 2539
2025
Q4 		$1.43M Buy
+28,697
New +$1.4M ﹤0.01% 2149
2022
Q4 		– Sell
-13,897
Closed -$470K – 3619
2022
Q3 		$470K Buy
13,897
+122
+0.9% +$3.97K 0.01% 1523
2022
Q2 		$398K Sell
13,775
-36,863
-73% -$1.06M 0.01% 1159
2022
Q1 		$1.64M Buy
+50,638
New +$1.55M 0.04% 432

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's SUPN Position: Q1 2026 in Review

Walleye Capital reduced its Supernus Pharmaceuticals (SUPN) stake by 61% in Q1 2026, selling an estimated $890K and leaving 11,214 shares worth $580K. The position accounts for ﹤0.01% of the portfolio, ranked #2539.

Walleye Capital first reported a position in SUPN in Q1 2022 and has held it in 5 quarters since. The position peaked at $1.64M in Q1 2022. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Walleye Capital held 11,214 shares of Supernus Pharmaceuticals worth $580K as of Q1 2026.
  • Walleye Capital sold 17,483 Supernus Pharmaceuticals shares in Q1 2026, an estimated $890K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2539 holding.
  • Walleye Capital first reported a position in Supernus Pharmaceuticals in Q1 2022 and has held it in 5 quarters since.
  • Walleye Capital's Supernus Pharmaceuticals position peaked at $1.64M in Q1 2022.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.